1 Preliminary Program and Registration Form January 2014

Preliminary Program and Registration Form
January 2014
1
10
th
International Symposium on Polymer Therapeutics:
From Laboratory to Clinical Practice
Monday 19th May – Wednesday 21st May 2014
Valencia, Spain
Chair: María J. Vicent (CIPF Valencia)
Co-Chair: Ruth Duncan (Cardiff, UK)
International Advisory Board
C. Alexander (Univ Nottingham, UK)
M. Ashford (AstraZeneca)
A. Basu (Natl Brain Res Center, India)
G. Battaglia (UCL, UK)
M. Bradbury (Memorial Sloan Kettering Cancer Center,
USA)
S. Brocchini (UCL, UK)
P. Caliceti (Univ Padua, Italy)
F. Caruso (Univ Melbourne, Australia)
S. Chipman (Aequus Biopharma Inc)
P. Dhal (Genzyme)
R. Gaspar (Univ Lisbon, Portugal)
H. Ghandehari (Univ Utah, USA)
P.C. Griffiths (Greenwich Univ, UK)
R. Haag (Free Univ Berlin, Germany)
J. Hrkach (Bind Biosciences)
S. Jain (Xenetic Biosciences Plc)
A. Kabanov (Univ. North Carolina, USA)
K. Kataoka (Univ. Tokyo, Japan)
M. Kavallaris (UNSW, Australia)
H. Kjaer Offenberg (NovoNordisk)
J. Kopecek (Univ. Utah, USA)
C. Li (M.D. Anderson Cancer Center, USA)
J. Lisziewicz (Genetic Immunity)
R Luxenhofer (Julius-Maximilians-Univ. Würzburg,
Germany)
SPONSORS INCLUDE (To be updated)
H. Maeda (Sojo Univ., Japan)
H. Maynard (UCLA, USA)
S. McNeil (NCL, USA)
Y. Nagasaki (Univ. Tsukuba, Japan)
M. Nicholas (Teva Pharmaceuticals, Israel)
D. Nowotnik (Access Pharmaceuticals)
D. Owen (StarPharma)
G. Pasut (Univ. Padua, Italy)
J Riggs-Sauthier (Nektar Therapeutics)
B. Rihova (Inst. Microbiol., Prague)
H. Ringsdorf (Univ. Mainz, Germany)
D. Shabat (Tel Aviv Univ, Israel)
C. Sailer (Sanofi Aventis)
J. San Roman (CSIC, Spain)
R. Satchi-Fainaro (Tel Aviv Univ)
H. Swai (CSIR, Pretoria)
J. Singer (Cell Therapeutics Inc)
S. Svenson (Cerulean Pharma)
K. Ulbrich (Inst Macro Chem, Czech Republik)
T. Viegas (Serina Therapeutics, USA)
E. Wagner (Univ. Munich, Germany)
S. White (CDRD, Univ. BC, Canada)
N. Zander (Fresenius Kabi)
R. Zentl (Univ Mainz, Germany)
EXHIBITORS INCLUDE (To be updated)
2
Background & Objectives

Polymer Therapeutics include biologically active polymeric drugs and polymeric sequestrants,
polymer-protein and polymer-drug conjugates, block copolymer micelles, and the
supramolecular assemblies that form multi-component polyplexes designed to promote
cytosolic delivery of genes, siRNAs and proteins. These constructs are amongst the most
successful first generation "Nanomedicines" with a growing number of products approved by
Regulatory Authorities for routine clinical use, and many others progressing through clinical
trials as single agents or as components of combination therapy regimes. The first follow-on
("generic") polymer therapeutics are emerging.

Ever more sophisticated synthetic chemistry is leading to complex three dimensional polymeric
architectures, including dendrimers, dendronised polymers and self-assembling nano-sized
particles, and many include new mechanisms for externally triggered degradation. Many are
being developed as imaging agents and theranostics. As clinical applications broaden to
include treatments for infectious and inflammatory diseases, tissue repair and regeneration,
and diseases of the ageing population there has been growing interest in the use of
biodegradable polymers that are more suited to use for chronic treatments.
Objectives Unlike other Drug Delivery Symposia that have a broader remit, this unique conference
series was specifically established to provide a forum for interdisciplinary exchange of state-of-theart techniques and advances in knowledge relating to the design, clinical development and
commercialisation of Polymer Therapeutics. The key topics discussed are
• POLYMERS - synthesis, safety, development to clinical use
• LINKERS - design, mechanisms for triggered degradation
• OPPORTUNITIES FOR TARGETING
• PROPOSED CLINICAL USE - models for determining in vitro and in vivo PK, PD, safety
• CURRENT CLINICAL STATUS
• INDUSTRIAL DEVELOPMENT AND REGULATION
th
The 10 International Symposium on Polymer Therapeutics will provide:
 World renown scientists to share with us their recent research and vision for the future of
Polymer Therapeutics in the context of interdisciplinary research at the interface of
biology, chemistry, pharmaceutical sciences and medicine.
 The latest developments in polymer technology and the biological and clinical disciplines
relating to Polymer Therapeutics.
 Industrial and medical progress in the transfer of Polymer Therapeutics from
Laboratory to Clinic.
 Finally, last but not least, this International Symposium will provide an opportunity for the
active participation of young scientists from around the world. A number of travel grants
will be available to support their attendance.
Who should attend?
- Academics active in, or recently joining the field of Polymer Therapeutics and
Nanopharmaceuticals,
- Industrialists, either active in the field, or requiring an update/introduction of the current status of
Polymer Therapeutics and issues relating successful translation from Lab to Clinic
- Post Doctoral Scientists and Postgraduate Students working in this interdisciplinary field
3
Abstracts
Deadline: 28th February 2014
(Abstracts received after the above deadline cannot be guaranteed to be accepted.)
_____________________________________________________________

ALL SPEAKERS to provide the single A4 page abstract according format/sample
below.


All DELEGATES are all encouraged to submit abstracts describing their latest work
(format/sample below).
Applications for travel grants must be accompanied by an abstract.

POSTERS will be displayed throughout the meeting (Portrait size 90 x 120 cm).

All Abstracts must be accompanied by a completed Registration Form with payment.
_____________________________________________________________
Instructions for preparation of abstracts (also see Sample)
• The abstracts are an important part of this interdisciplinary meeting and the text should
be understandable to the inter-disciplinary readership. Thus the “Introduction” and
“References” sections of the abstract are particularly important.
All Abstracts will be reproduced Camera Ready in the Symposium Proceedings and the
Proceedings will be published as of the Conference date.
Single page of A4 text only. font : size 12 (Times), single spacing
Authors, Presenting Author first, Addresses (Centered)
INTRODUCTION (Headings Bold Caps)
RESULTS AND DISCUSSION
REFERENCES Font size 12 or 10 - up to 5 key references
4
SAMPLE ABSTRACT FORMAT
POLYMER CONJUGATES AS PLATFORMS FOR COMBINATION THERAPY IN THE
TREATMENT OF HORMONE-DEPENDENT CANCERS
Coralie Deladriere1, Esther Masiá1, Francesca Greco 2, Rut Lucas1, María J. Vicent1
1
Centro de Investigación Príncipe Felipe. Polymer Therapeutics Laboratory. Av. Autopista del
Saler,16, 46012 Valencia, Spain. 2 School of Pharmacy, University of Reading, Whiteknights PO
BOX 224 Reading RG6 6AD Berkshire, UK.
INTRODUCTION
The use of polymer-drug conjugates in combination therapy is seen as an important opportunity to enhance tumour
response rates1. The polymeric carrier provides an ideal platform for the delivery of a cocktail of drugs simultaneously.
It can be hypothesised that the combination of endocrine therapy with a chemotherapeutic agent by simultaneous
covalent binding to the same polymer chain would bring significant advantage. The combination could be administrated
as single dose and therefore benefits would be found in drug synergism, patience compliance and conjugate
manufacturing1. We have previously reported the first endocrine-chemotherapy combination in the form of the model
compound HPMA copolymer-aminoglutethimide (AGM)-doxorobucin (Dox)2. It was discovered that the conjugate
containing both drugs showed markedly enhanced cytotoxicity compare with HPMA copolymer-Dox, a conjugate that
has already show clinical activity in breast cancer patients3 , whereas mixtures of polymer conjugates containing only
AGM or Dox did not show a synergistic benefit4. In order to further improve this construct, we now propose the use of
a biodegradable and multivalent polymer poly(L-glutamic acid) (PGA) being able to increase drug loading capacity and
conjugate Mw enhancing therefore its tumour targeting by the EPR effect. Additionally, a High Throughput Screening
(HTPS) approach has been developed in order to identify new and efficient drug combinations for breast cancer
treatment.
RESULTS AND DISCUSSION
A family of PGA-AGM ±Dox conjugates has been obtained using a DIC-mediated coupling. Physico-chemical
characterization of the single as well as the combination conjugates has been accomplished. The conjugates were
completely stable under hydrolitical conditions up to 72h but were degraded in presence of the lysosomal enzyme
cathepsin B releasing the drug in a time-dependent manner clearly depending on the polymer-drug linker used.
Adequate drug(s) release kinetics is a key parameter to achieve synergism with combination conjugates.4 In order to
design an adequate combination polymer, peptidic linkers with an adequate drug kinetic profile have been selected from
single AGM and Dox conjugates. PGA-AGM-Dox conjugate bearing GlyPheLeuGly has been also synthesised to allow
direct comparison with the model combination conjugate HPMA-AGM-Dox2,4. LC-MS technique was used to elucidate
specific cleavage site. pH labile linkers are currently being explored. Biological evaluation of the conjugates
synthesised are being carried out in MCF-7 and MCF7-ca cell lines looking at cell viability as well as specific
molecular cascades.
REFERENCES
1 Greco F. and Vicent M.J. (2009) Polymer conjugates based combinations for improved treatment of cancer. Adv.
Drug Deliv. Rev. 61(13), 1203.
2. Vicent, M.J. et al. (2005) Polymer Therapeutics designed as a Novel Combination Therapy for the Treatment of
Hormone-Dependent Cancer. Angew. Chem. Int. Edit. 44, 2.
3. Vasey, P.A. et al.(1999). Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide
copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer
Research Campaign Phase I/II Committee. Clin. Cancer Res. 5, 83.
4. Greco, .F et al. (2007) Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in
breast cancer cells.. J. Control Rel: 13, 459.
5
REGISTRATION
PLEASE NOTE that participation will be limited to ~ 200 delegates. The last conference was
oversubscribed. Early registration is recommended to secure a place.
Registration should be made on the attached registration form and must be accompanied by the full
payment.
Cancellation Policy: A refund of 80% will be made in case of cancellation before end March 2014 (a
handling fee is charged). After this date no refunds will be made.
APPLICATIONS FOR A TRAVEL GRANT - PhD students and Early Career Scientists without access to
travel funds- should indicate their intention to apply for a Travel Grant on the Registration Form and also
send:



A supporting letter from their PhD supervisor (students) or Head of Department
Only those applicants also submitting an Abstract will be considered for a travel grant.
The number of Awards made will be dependent on the Sponsorship funds available and all successful
applicants will be notified by end March 2014.
_______________________________________________________________________
ACCOMMODATION AND LOCAL ARRANGEMENTS
Venue: All lectures and the Poster Session will take place at ‘Centro de Investigación Príncipe Felipe’, Av.
Eduardo Primo Yúfera 3, E-46012, Valencia, Spain
Meeting Schedule: The Meeting will commence at ~ 9.00 am on Monday 19th May 2014 (Registration
From 7.45 am) and end at lunchtime on Wednesday 21st May 2014. (This will allow those delegates who
wish to do so the opportunity to arrange side meetings on the afternoon of Wednesday 21st)
______________________________
Travel: The CIPF is located next to the famous “Ciudad de las Artes y las Ciencias” in Valencia (see
http://www.cipf.es/Ubicacion/?lang=en for map)
By Air: Valencia International Airport is served by low cost airlines from most of European cities. Most
intercontinental flights arrive at Barcelona or Madrid in Spain and many other major European cities.
• Travel from the airport to Valencia city center takes ~ 20 min by taxi (costs ~ 25€).
There is also an Aero-bus from the airport to city center (tickets: €2.50) and a direct underground line
connection to city center. The metro station is at the ground floor of the regional flights terminal (tickets:
€1.70) (see map at http://www.metrovalencia.com). The journey takes around 25 minutes.
• Detailed information on travel to and airport can be found at http://www.valencia-cityguide.com/touristinformation/transport/transport-from-the-airport-to-the-city.html.
Alicante International Airport is also served by many
flights from most European cities including low cost
airlines such as bmibaby or Easyjet. A taxi from Alicante
Airport to the Alicante train station (costs ~20 €) where a
Euromed train can be taken from Alicante to Valencia
(cost. ~40 € return, ~ 2 hours trip)
Barcelona International Airport El Prat is also served
by many flights from most European cities including low
cost airlines. A direct train can be taken from El Prat
Airport to Barcelona Sans Train station. From there the
Euromed train can be taken from Barcelona to Valencia
(cost. ~70 € return, 3 hours trip)
By Train
There are trains every hour from Madrid (Ave from
Atocha) or Barcelona (Euromed from Sans Estació) Train
Station to Valencia Joaquín Sorolla. The journey time is 1.40 h from Madrid and 3 h from Barcelona (it is
highly recommended to book and buy your train tickets in advance, electronic tickets available at
http://www.renfe.es). There are also trains every hour from Alicante train station to Valencia Estación del
Norte or Valencia Joaquín Sorolla (journey time ~ 2 h).
6
________________________________________________________________________
Weather: Valencia in spring is very pleasant. It has a Mediterranean climate, which is mainly sunny and with
temperatures usually between 20- 25 ºC.
Accommodation: There are many hotels within 10-15 minutes’ walk of the conference (CIPF) all price
ranges. Delegates are requested to book their own accommodation. Below are some suggestions.
PLEASE book your accommodation early as possible as Valencia hosts many International events and room
availability can be limited.
Suggested Hotels (see map)
These are some of the closest hotels surrounding the institute
1. NH Express Las Artes 3* Instituto Obrero de
Valencia, 26, Valencia.
NH Express Las Artes 4* Instituto Obrero de
Valencia, 26, Valencia.
2. Barceló Valencia 4* Av. Francia 11, Valencia.
3. Tryp Oceanic 4* Pintor Maella 35, Valencia.
4. Hotel Valencia Center 4* Avda. de Francia,
s/n, Valencia.
5. Abba Acteón 4* Escultor Vicente Beltrán
Grimal, 2, Valencia.
6. AC Hotel 4* Av. Francia s/n, Valencia
7. Holiday Inn Valencia 4* Paseo De La Alameda,
38, Valencia.
8. Confortel Aqua 4 4* Luis Garcia Berlanga 19-21,
Valencia.
Confortel Aqua 3 3* Menorca, S/N, Valencia.
9. Beatriz Rey Don Jaime 4* Avenida de
Baleares 2, Valencia.
10. Hotel Husa Serrano 3* General Urrutia, 48,
Valencia.
CIPF
More hotel/hostel suggestions can be found at: http://www.valencia-cityguide.com/accommodation/hotels-accommodation.html
7
PROVISIONAL LIST OF SPEAKERS (January 2014)
(Further names to be added relating to ongoing clinical studies & from submitted abstracts)
Plenary Lectures
• Jan Schnitzer (PRISM, San Diego) - Vascular targeting via caveolar pathways: opportunities for tumour
and lung-specific delivery
• Marianne Ashford (AstraZeneca, UK) - Designing nanomedicines to Improve the therapeutic Index of
drugs
• David Kirsch (Duke University Medical Center, NC) - Use of novel tumour imaging approaches to
characterise tumour vasculature and cathepsin activated fluorescent probes to distinguish between
normal and cancerous tissue: Preclinical and Clinical Experience
Invited Lectures
Synthesis/Novel Approaches
• G Pasut (Univ. Padua) - Synthesis and characterization of PEOZ, PGA and HA-protein conjugates:
Alternatives to PEG-conjugates?
• Julio San Roman (Inst. Materiales CSIC, Madrid) - Self-assembling gradient copolymers of
vinylimidazol and (acrylic) ibuprofen with anti-Inflammatory and zinc chelating properties
• David Lewis (Arrowhead Research Corporation) - Dynamic Polyconjugates™ for siRNA delivery
• Jianjun Cheng (Univ. Illinois) - Chain-shattering polymeric therapeutics with on-demand drugrelease : Use of UV- or hydrogen peroxide-responsive domains
• Arne Skerra (XL-Protein GmbH) - PASylation: a biological alternative to PEGylation for extending the
plasma half-life of pharmaceutically active proteins and peptides
Analytical Tools
• E Zagar (National Institute of Chemistry, Ljubljana) - Asymmetrical-flow field-flow fractionation and size
exclusion chromatography for characterisation of polymer-protein conjugates
• Peter Griffiths (Univ. Greenwich) - Using SANS and NMR to study diffusion, solution conformation and
membrane interaction
• Silvia Muro (Univ. Maryland) - Endocytosis and intracellular trafficking: Understanding the Importance of
acute and Chronic Shear Stress on targeting and opportunities for intracellular drug delivery
Diseases:Cancer/Drug Combinations & Imaging
• Ronit Satchi-Fainaro (Tel Aviv Univ.) - Combination nanomedicines for personalized cancer theranostics
• Hamid Ghandehari (Univ. Utah) - Guided delivery of polymer therapeutics using plasmonic photothermal
therapy
• Chris Porter (Monash Inst. Pharm. Sci.) - Polylysine dendrimers for the delivery of anticancer agents and
lymphatic targeting
• Helen Burt (Univ. British Colombia) - Preclinical development of hyperbranched polyglycerol based
nanoparticles for treatment of bladder cancer
Other Diseases
• Hidetoshi Arima (Kumamoto Univ) - Lactosylated dendrimer/α-cyclodextrin conjugates for systemic
delivery of transthyretin siRNA into hepatocytes for treatment of familial amyloidotic polyneuropathy.
• A V Kabanov (Univ. North Carolina, Chapel Hill) - Fullerenes, polymer complexes and polymer
conjugates: Potential for the treatment of brain related diseases
Products in Clinical Development/Clinical Use
• Phil Rye (Algipharma) - Aliginate oligosaccardides for the treatment of cytstic fibrosis
• Jack Singer (CTI) - Update on the clinical development of Opaxio in ovarian, head and neck and
glioblastoma
• Sanjay Jain (Xenetic Biosciences plc) - Phase II clinical studies with ErepoXen® (polysialyated insulin)
and Phase III clinical update
• Tetsuya Hamaguchi (National Cancer Center Hospital, Tokyo) - Clinical evaluation of nanomicelles
and preclinical study of antibody conjugated micellar formulation
• Chris Twelves (Univ. Leeds, UK) - Etirinotecan pegol Target-Specific Pharmacodynamic (PD)
Biomarkers Measured in Circulating Tumor Cells (CTCs) from Patients in the Phase 3 BEACON Study in
Patients with Metastatic Breast Cancer (mBC)
Development from lab to clinic, Post Marketing Experience & Follow-On products
• Lucia Del Vecchio (Ospedale A. Manzoni, Lecco) - Peginesatide as a new approach for treating
anemia of CKD patient: is it like a falling star?
• Mike Nicholas (Teva Pharmaceuticals) - The complexity of Copaxone and life cycle management issues
• Sam White (Centre for Drug Research and Development (CDRD), Univ. British Columbia) Translating Ideas from Research to Commercial Products
• Brij Patel (RegExcelconsulting) - Manufacturing and regulatory challenges for nanomedicines/polymer
therapeutics.
8
Discussion Leaders will include (many will also present their latest research)

Yukio Nagasakai (Univ. Tsukuba, Japan)
 Maria Kavallaris (UNSW, Australia)
 Ruth Duncan (Cardiff, UK)
 Matthias Barz (Univ. Mainz, Germany)
 Rogerio Gaspar (Univ. Lisbon, Portugal)
 Robert Luxenhofer (Julius-Maximilians-Univ.
Würzburg, Germany)
 Hiroshi Maeda (Sojo Univ., Japan)
 Philipp Seib (Univ. Strathclyde, UK)
 Pradeep Dhal (Genzyme-Sanofi Aventis, USA)
 Chun Li (M.D. Anderson Cancer Center)
 Karel Ulbrich (Academy Sciences Czech Republic)
 David Thomas (Cardiff Univ., UK)
 Alexander Zelikin (iNano, Denmark)
 Michelle Bradbury (MSKCC,USA)
9
10th International Symposium on Polymer Therapeutics:
From Laboratory to Clinical Practice
Monday 19th May – Wednesday 21stMay 2014



Participation is limited to ~200 delegates and registration can only be accepted with full
payment. No refunds will be made after March 30th 2014.
Abstract Submission must be accompanied by registration and payment
All recipients of Travel Grant Awards will be notified by March 2014 and the award will be paid
by cheque at The Symposium
The registration fee includes a copy of the Symposium Proceedings, tea/coffee, the
Welcoming Dinner on Monday evening and lunches on Monday and Tuesday
Please tick
I wish to attend to the Welcoming Dinner on Monday 19th May
Registration Fee
Before 15th March
(VAT excluded)
Industry
Academic
Postgraduate Student†
600 €
450 €
200 €
After 15th March
2014
750 €
550 €
300 €
†
Postgraduate student applications must be supported by letter from their
supervisor confirming student status
†
I wish to be considered for a Travel Grant Award and enclose an Abstract, Supporting
Letter from my Supervisor and/or Head of Department, and the Registration Fee
Please Print or Type
Name:
Address:
Passport n.:
If industrial participant, company VAT number:
Tel:
E-mail:
Fax:
Amount paid
€
Form of payment: All payments must be made by bank transfer.
Bank account in BANKIA. Concept: 10th Int. Symp. Polymer Therapeutics (person name)
Bank Transfer: 2038 9938 4160 0020 4038
International Bank Transfer. IBAN: ES14 2038 9938 4160 0020 4038
SWIFT/BIC: CAHMESMMXXX
Signed ...............................................
Date .................................................
Please send proof of bank transfer with Registration (pdf copy) to:
Dr María J. Vicent,
Polymer Therapeutics Lab. 10th ISPT: LtoC.
Centro de Investigación Príncipe Felipe
Av. Autopista del Saler 16, E-46012 Valencia, Spain
Fax: +34963289701 or E-mail: [email protected]
10